| ID | 116353 |
| 著者 | |
| キーワード | Obesity
Liraglutide
Semaglutide
Glucagon like peptide-1receptor agonists (GLP-1RAs)
Glucose-dependent insulinotropic polypeptide (GIP)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Obesity has been crucial diseases. Several agents have been used including Phentermine, Mazindol, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion and Liraglutide from 1959 to present. Glucagon like peptide-1receptor agonists (GLP-1RAs) has been used for type 2 diabetes mellitus (T2DM). As GLP-1RA, liraglutide is given 0.9 mg/day for T2DM, and 3.0 mg/day for obesity. Similary, semaglutide is given 1.0 mg/week for T2DM and 2.4 mg/week for obesity. Semaglutide brought 14.9% weight reduction for 68 weeks. There is a novel combination of GLP-1RA and glucose-dependent insulinotropic polypeptide (GIP) for treating obesity, which achieved at least 10% weight reduction in 6-39% of cases for 26 weeks.
|
| 掲載誌名 |
Journal of Diabetes, Obesity & Metabolism
|
| 出版者 | Yumed Text
|
| 巻 | 4
|
| 号 | 2
|
| 開始ページ | e107
|
| 発行日 | 2021-08-09
|
| 権利情報 | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
|
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
